Alzheimer's Drug Discovery Foundation

90 articles about Alzheimer's Drug Discovery Foundation

• ADDF Statement on New Results from Donanemab's TRAILBLAZER-ALZ 2 Trial

  7/17/2023

  The Alzheimer's Drug Discovery Foundation is encouraged to see the positive data reported by Eli Lilly and Company for its anti-amyloid drug, donanemab, which was unveiled at the Alzheimer's Association International Conference in Amsterdam and published in JAMA.

• ADDF Statement on Topline Results from Phase 3 Trial of Amyloid-Clearing Drug Donanemab

  5/3/2023

  The Alzheimer's Drug Discovery Foundation (ADDF) is encouraged to see the positive data reported today by Eli Lilly and Company for their amyloid-clearing antibody donanemab.

• Lauder Family Donates $200 Million to Alzheimer's Drug Discovery Foundation for Development of Novel Methods to Prevent, Diagnose, Treat, and Cure Alzheimer's Disease

  4/4/2023

  The Alzheimer's Drug Discovery Foundation announced that Leonard A. Lauder and Ronald S. Lauder, along with the entire third generation of their family, William Lauder, Gary Lauder, Aerin Lauder Zinterhofer, and Jane Lauder, have committed $200 million to accelerate the discovery and development of drugs to prevent and treat Alzheimer's disease.

• ADDF Statement on Gantenerumab Data Presented at CTAD

  12/1/2022

  The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer's Disease conference demonstrate why optimal treatment of Alzheimer's will require drugs that do more than clear amyloid plaques.

• ADDF Statement on Lecanemab Data Presented at CTAD

  11/30/2022

  Based on study results presented at the 15th Clinical Trials on Alzheimer's Disease conference and published in The New England Journal of Medicine, amyloid-clearing drug lecanemab—poised for FDA approval early next year—will be a positive step in the treatment of Alzheimer's.

• Dr. Miranda Orr Wins Alzheimer's Drug Discovery Foundation's Prestigious Melvin R. Goodes Prize

  9/22/2022

  The Alzheimer's Drug Discovery Foundation has named Miranda E. Orr, PhD, Assistant Professor of Gerontology and Geriatric Medicine at the Wake Forest University School of Medicine, as the recipient of the 2022 Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Development.

• 

  Research Ramps Up in Alzheimer's, Parkinson's, MS and ALS

  9/19/2022

  Research on Alzheimer's, specifically in neuroscience, continues with the Alzheimer's Drug Discovery Foundation, Critical Path Institute, Abbvie, AlzeCure Pharma and more. 
• 

  Philanthropic Donations and Debt Financings Rake in Cash for Cancer, Alzheimer's and Mental Healt...

  7/29/2022

  Money on the Move: ​​​​​​​A weekly roundup of notable funding news across biopharma industry. See who raked in funds for which diseases

• Leonard A. Lauder, Bill Gates and Jeff Bezos Joined by New Partners in $100M Global Research Effort to Answer Urgent Need for Early Detection of Alzheimer's Disease

  7/26/2022

  The Alzheimer's Drug Discovery Foundation announces the second phase of its Diagnostics Accelerator with new philanthropic partners and an additional $50 million in financial commitments, bringing the total capital to $100 million earmarked to speed development of new and innovative tests for early diagnosis of Alzheimer's disease and related dementias.

• Alzheimer's Drug Discovery Foundation and Harrington Discovery Institute Invite Proposals for 2022 ADDF-Harrington Scholar Award

  6/17/2022

  Harrington Discovery Institute at University Hospitals and the Alzheimer's Drug Discovery Foundation announce a joint request for proposals for the 2022 ADDF-Harrington Scholar Award.

• Alzheimer's Drug Discovery Foundation Awards Dr. Miia Kivipelto Esteemed Melvin R. Goodes Prize

  10/29/2021

  The Alzheimer's Drug Discovery Foundation has named Dr. Miia Kivipelto as the recipient of the 2021 Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery.

• Fujirebio Europe Receives Translational Research Funding From Alzheimer’s Drug Discovery Foundation for Development of a Fully Automated Plasma pTau181 Testing Solution

  10/28/2021

  H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio, announced an agreement with the Diagnostics Accelerator initiative of the Alzheimer's Drug Discovery Foundation to accelerate the development of a plasma pTau181 detection assay on the fully automated LUMIPULSE® G immunoassay platform.

• Alzheimer's Drug Discovery Foundation (ADDF) Investment Boosts Search for Digital Biomarkers for Early Alzheimer's

  7/26/2021

   The Alzheimer's Drug Discovery Foundation has announced up to $2 million of funding for a collaborative research initiative led by UK charity Alzheimer's Research UK that aims to develop a digital Toolkit of apps and wearables to detect the very earliest stage of Alzheimer's.

• The Alzheimer's Drug Discovery Foundation and Harrington Discovery Institute to Support Promising Research to Restore Brain Function in People with Alzheimer's Disease

  7/1/2021

  The Alzheimer's Drug Discovery Foundation and Harrington Discovery Institute at University Hospitals in Cleveland have granted ADDF-Harrington Scholar Awards to two Principal Investigators, Paul Fish, Ph.D., of University College London's Drug Discovery Institute and Paul Worley, M.D., of Johns Hopkins University.

• Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator Expands Its Investments in Digital Biomarkers for Early Alzheimer's Diagnosis

  6/16/2021

  The Alzheimer's Drug Discovery Foundation Diagnostics Accelerator announced four new research investments for development of digital biomarkers for Alzheimer's diagnosis.

• Foundation For a Better World Honors Alzheimer's Drug Discovery Foundation with Inaugural Claugus Award

  5/13/2021

  The Foundation For a Better World recently honored the Alzheimer's Drug Discovery Foundation with the inaugural Claugus Award for its commitment and dedication to Alzheimer's research.

• Alzheimer's Drug Discovery Foundation Appoints Christopher Johnson Co-Chair of Board of Overseers

  2/26/2021

  The Alzheimer's Drug Discovery Foundation, a leading nonprofit solely focused on accelerating the development of drugs for Alzheimer's disease and related dementias, announces that Christopher Johnson, CEO of Rackson Restaurants, has been appointed as Co-Chair of the ADDF's Board of Overseers.

• The Alzheimer's Drug Discovery Foundation Appoints Karen Harris, Chief Financial Officer, and Dr. Mark Forman, Senior Director of Drug Development

  2/25/2021

  The Alzheimer's Drug Discovery Foundation, a leading nonprofit solely focused on accelerating the development of drugs for Alzheimer's disease and related dementias, announced a significant expansion of its leadership team with the hiring of Karen Bettauer Harris as chief financial officer and Dr. Mark S. Forman as senior director of drug development.

• The Alzheimer's Drug Discovery Foundation Announces New Additions to Board of Governors

  1/15/2021

   The Alzheimer's Drug Discovery Foundation (ADDF) announces two new members to its Board of Governors : Sharon T. Sager , CIMA, Managing Director and Private Wealth Advisor at UBS Private Wealth Management and Beatriz Illescas Putzeys-Claugus , Founder and Director of The Foundation for a Better World. They will help guide the ADDF in

• The Alzheimer's Drug Discovery Foundation and The Association for Frontotemporal Degeneration Invite Proposals for 2021 Treat FTD Fund

  12/15/2020

   The Association for Frontotemporal Degeneration (AFTD) and the Alzheimer's Drug Discovery Foundation (ADDF) issued a joint request for proposals (RFP) targeting novel research to advance and accelerate ways to diagnose and treat frontotempora